AI-assisted Subtyping-directed Precision Treatment in Acute Aortic Dissection
Starting soon · Not applicable
Conditions studied: Aortic Aneurysm and Dissection
In brief
Aortic dissection has acute onset and high mortality, with immunoinflammatory response driving lesion progression. Current perioperative anti-inflammatory therapies are mostly empirical and poorly targeted, and AI-assisted typing lacks a complete clinical translation pathway. This study integrates multi-dimensional data to construct an AI immunoinflammatory subtyping system, enabling rapid subtyping and establishing a "subtyping-target-treatment" closed loop for emergency needs. Using a prospective multicenter RCT, 300 patients are randomly divided into two groups: the experimental group receives subtyping-based precision therapy, while the control group uses empirical strategies (treatment of physician's choice). It observes 7-day postoperative SOFA score, SIRS and other prognostic indicators to provide evidence-based support for precision treatment.
Key facts
- Study ID
- NCT07382375
- Run by
- Nanjing Medical University
- People needed
- 300
- Starts
- 2027-12-31
- Expected to finish
- 2027-12-31
- Last updated by the study team
- 2026-02-02
Who can join
Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Confirmed diagnosis of acute aortic dissection by contrast-enhanced Computed Tomography Angiography (CTA) or Magnetic Resonance Angiography (MRA);
- Planned emergency surgical treatment (including open surgery and endovascular repair);
- Aged 18-80 years old, regardless of gender;
- Time from onset to hospital admission ≤ 72 hours;
- Signed informed consent form by the patient or their authorized agent, with willingness to cooperate with the follow-up of the study.
You may not qualify if…
- Complicated with underlying diseases that affect immunoinflammatory status, such as severe infections (e.g., sepsis, infective endocarditis), autoimmune diseases, malignant tumors, chronic liver diseases, and chronic kidney diseases (uremic stage);
- Long-term use of immunosuppressants or glucocorticoids before surgery (continuous use for ≥ 2 weeks);
- Pregnant or lactating women;
- Patients with mental disorders or cognitive dysfunction who cannot cooperate with the study.
Where it is running
- Beijing Anzhen Hospital — Beijing, China
- Changzhou First People Hospital — Changzhou, China
- West China Hospital of Sichuan University — Chengdu, China
- Fujian Medical University Union Hospital — Fuzhou, China
- The First Affiliated Hospital of Guangzhou Medical University — Guangzhou, China
- Nanchang University Second Hospital — Nanchang, China
- The First Affiliated Hospital of Nanjing Medical University — Nanjing, China
- Shanghai East Hospital — Shanghai, China
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.